These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34342720)

  • 21. Chronic opioid treatment augments caveolin-1 scaffolding: relevance to stimulatory μ-opioid receptor adenylyl cyclase signaling.
    Chakrabarti S; Chang A; Liu NJ; Gintzler AR
    J Neurochem; 2016 Dec; 139(5):737-747. PubMed ID: 27726130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mu opioid receptor: A new target for cancer therapy?
    Singleton PA; Moss J; Karp DD; Atkins JT; Janku F
    Cancer; 2015 Aug; 121(16):2681-8. PubMed ID: 26043235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioids: Modulators of angiogenesis in wound healing and cancer.
    Ondrovics M; Hoelbl-Kovacic A; Fux DA
    Oncotarget; 2017 Apr; 8(15):25783-25796. PubMed ID: 28445930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing safer analgesics: a focus on μ-opioid receptor pathways.
    Pergolizzi JV; LeQuang JA; Taylor R; Ossipov MH; Colucci D; Raffa RB
    Expert Opin Drug Discov; 2018 Oct; 13(10):965-972. PubMed ID: 30175624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining opioids and non-opioids for pain management: Current status.
    Li JX
    Neuropharmacology; 2019 Nov; 158():107619. PubMed ID: 31029588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IRAS Modulates Opioid Tolerance and Dependence by Regulating μ Opioid Receptor Trafficking.
    Li F; Ma H; Wu N; Li J
    Mol Neurobiol; 2016 Sep; 53(7):4918-30. PubMed ID: 26363797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opiate antagonist prevents μ- and δ-opiate receptor dimerization to facilitate ability of agonist to control ethanol-altered natural killer cell functions and mammary tumor growth.
    Sarkar DK; Sengupta A; Zhang C; Boyadjieva N; Murugan S
    J Biol Chem; 2012 May; 287(20):16734-47. PubMed ID: 22451667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of opioids and mu-opioid receptors on oncologic metastasis.
    Wang R; Li S; Wang B; Wang G; Zheng H
    Am J Cancer Res; 2024; 14(9):4236-4247. PubMed ID: 39417177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
    Mathew B; Lennon FE; Siegler J; Mirzapoiazova T; Mambetsariev N; Sammani S; Gerhold LM; LaRiviere PJ; Chen CT; Garcia JG; Salgia R; Moss J; Singleton PA
    Anesth Analg; 2011 Mar; 112(3):558-67. PubMed ID: 21156980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance.
    Garzón J; Rodríguez-Muñoz M; Sánchez-Blázquez P
    Curr Drug Abuse Rev; 2012 Sep; 5(3):199-226. PubMed ID: 22920535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia.
    Oladosu FA; Conrad MS; O'Buckley SC; Rashid NU; Slade GD; Nackley AG
    PLoS One; 2015; 10(8):e0135711. PubMed ID: 26270813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agonist-dependent attenuation of mu-opioid receptor-mediated G-protein activation in the dorsal root ganglia of neuropathic rats.
    Obara I; Gunduz Cinar O; Starowicz K; Benyhe S; Borsodi A; Przewlocka B
    J Neural Transm (Vienna); 2010 Apr; 117(4):421-9. PubMed ID: 20213428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors.
    Gerak LR; Maguire DR; France CP
    Handb Exp Pharmacol; 2020; 258():127-145. PubMed ID: 31451969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel GPCR paradigms at the μ-opioid receptor.
    Thompson GL; Kelly E; Christopoulos A; Canals M
    Br J Pharmacol; 2015 Jan; 172(2):287-96. PubMed ID: 24460711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.
    Gach K; Szemraj J; Fichna J; Piestrzeniewicz M; Delbro DS; Janecka A
    Chem Biol Drug Des; 2009 Oct; 74(4):390-6. PubMed ID: 19691469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
    Datta U; Kelley LK; Middleton JW; Gilpin NW
    Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain.
    Mousa SA; Cheppudira BP; Shaqura M; Fischer O; Hofmann J; Hellweg R; Schäfer M
    Brain; 2007 Feb; 130(Pt 2):502-13. PubMed ID: 17142830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphine as a treatment of cancer-induced pain-is it safe? A review of in vivo studies and mechanisms.
    Brinkman D; Wang JH; Redmond HP
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Nov; 391(11):1169-1178. PubMed ID: 30232510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
    Milan-Lobo L; Whistler JL
    J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural and functional interactions between six-transmembrane μ-opioid receptors and β2-adrenoreceptors modulate opioid signaling.
    Samoshkin A; Convertino M; Viet CT; Wieskopf JS; Kambur O; Marcovitz J; Patel P; Stone LS; Kalso E; Mogil JS; Schmidt BL; Maixner W; Dokholyan NV; Diatchenko L
    Sci Rep; 2015 Dec; 5():18198. PubMed ID: 26657998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.